国药现代公告称，公司及下属子公司参加国家集采药品第1 - 8批协议期满品种接续采购，49个药品拟中 选。拟中选药品采购周期至2028年12月31日，2024年度销售收入22.52亿元，占同期营收20.59%；2025 年前三季度销售收入16.02亿元，占同期营收23.15%，无单一品种收入超同期营收5%。本次采购总体价 格稳定，部分或下降，拟中选结果待确认，后续情况存在不确定性。 ...

本次接续采购是国家组织集采药品第1-8批协议期满品种接续采购，根据本次接续采购规则，公司暂无 法获知准确的供应价格及供应数量。本次拟中选药品的采购周期为自中选结果执行之日起至2028年12月 31日。 本次接续采购总体上保持价格稳定，部分品种或进一步下降。采购周期中，医疗机构将优先使用本次接 续采购中选药品，并确保完成约定采购量。本次拟中选药品后续签订购销合同并实施后，有利于最大程 度稳固公司拟中选产品现有市场份额，有利于提升公司的品牌影响力和市场竞争力。上述事项对公司当 期经营业绩不会产生重大影响。 格隆汇2月11日丨国药现代(600420.SH)公布，公司及部分下属子公司参加了国家组织集采药品协议期满 品种接续采购办公室（简称接续采购办公室）组织的国家集采药品第1-8批协议期满品种接续采购（以 下简称本次接续采购）。根据接续采购办公室于2026年2月10日发布的《国家组织集采药品协议期满品 种接续采购拟中选结果公示》，公司及下属子公司合计51个药品拟中选本次接续采购。 ...

Group 1 - The core viewpoint of the article emphasizes the company's commitment to sustainable business development and innovative transformation [1] - The company focuses on its core responsibilities and continuously upgrades its marketing model to enhance quality, reduce costs, and strengthen integrated supply chain construction [1] - The company adheres to a strategy of "technology leadership and innovation-driven" to improve its strategic layout in the supply chain, aiming to fill gaps in the existing supply chain [1] Group 2 - The company is concentrating on assets with certain advantages in niche areas and is exploring various external development paths, including equity investments, pipeline acquisitions, technology licensing, and research collaborations [1]

（编辑 王雪儿） 证券日报网讯 2月9日，国药现代在互动平台回答投资者提问时表示，医药研发具有周期长、投入大、 风险高的特性，公司将坚持"创新驱动"发展战略，深化合作创新，努力推动创新突破。如有重大事项公 司将及时履行信息披露义务。请以公司后续公告及定期报告披露信息为准。 ...

Group 1 - XianDao Intelligent has set the final price for its H-share public offering at HKD 45.8 per share, with expected listing on February 11, 2026 [1] - Jida Communication is a candidate for a project with China Mobile, with an estimated service fee of approximately CNY 51.04 million [2] - Bowei Alloy's controlling shareholder plans to increase holdings by CNY 100 million to 150 million from February 10 to August 9, 2026 [3] Group 2 - Xiamen Airport reported 16,368 aircraft takeoffs and landings in January 2026, a year-on-year decrease of 4.82%, with passenger throughput of 2.38 million, down 3.84% [4] - Yitong Century has won a bid for a project worth CNY 107 million, providing comprehensive maintenance services for China Tower [5] - Huayi Brothers' controlling shareholder's 70 million shares are subject to judicial auction, representing 42.89% of his holdings and 2.52% of the company's total shares [6] Group 3 - Lianhuan Pharmaceutical received approval for the sale of Tadalafil tablets (20mg) in Ghana [7] - Aonong Biological reported a pig sales volume of 166,600 in January 2026, a year-on-year increase of 35.36% [8] - Xiantan Co. achieved chicken product sales revenue of CNY 546 million in January 2026, a year-on-year increase of 54.9% [9] Group 4 - Zhengbang Technology reported a January sales revenue of CNY 816 million from pig sales, a year-on-year increase of 19.69% [10] - Qianjin Pharmaceutical's net profit for 2025 grew by 24.74% to CNY 288 million [11] - Xinhua Pharmaceutical received a drug registration certificate for glucosamine sulfate capsules [12] Group 5 - Yuandong Bio completed the first dosing of its EP-0210 monoclonal antibody in a Phase I clinical trial for inflammatory bowel disease [13] - Jiaokong Technology signed a contract for the Sydney Metro West Line signal system subcontracting project worth AUD 93.53 million [14] - Dangsheng Technology signed a strategic cooperation framework agreement with Huineng Technology in solid-state batteries and the new energy industry [15] Group 6 - Jinhui Co. plans to acquire 100% of Fusheng Mining for CNY 210 million [16] - Cangzhou Mingzhu announced Guangzhou Light Industry as its new controlling shareholder after a share transfer [17] - Dingxin Technology's vice president was fined CNY 120,000 for short-term trading [18][19] Group 7 - China Modern Pharmaceutical's subsidiary passed a GMP compliance inspection for its production line [20] - Chaosheng Electronics plans to increase capital by CNY 400 million in its subsidiary to enhance competitiveness [21] - Lonyu Mountain reported a 25.03% year-on-year increase in pig sales revenue in January 2026 [22] Group 8 - Sanbo Brain Science's chairman has been released from investigation, and the company is operating normally [23] - Hainan Mining is planning to acquire control of Luoyang Fengrui Fluorine Industry and will resume trading on February 10, 2026 [24] - Dongwei Technology's net profit for 2025 increased by 86.81% [25] Group 9 - Yuanjie Technology plans to invest CNY 1.251 billion in a semiconductor chip and device R&D production base [26] - Metro Design signed a contract for an energy management project with Guangzhou Metro Group worth CNY 924 million [27] - Zhongmin Energy intends to acquire 51% of Fujian Yongtai Mintou Pumped Storage Co. for CNY 864 million [28] Group 10 - Dianzhi Technology plans to repurchase shares worth CNY 100 million to 200 million [29] - China Baoan was not selected as a restructuring investor for the Singshan Group [30] - Zhiguang Electric's subsidiary signed a CNY 1.004 billion contract for energy storage systems [31] Group 11 - Zhifei Biological received approval for a clinical trial of its herpes zoster vaccine [32] - KQ Bio received a new veterinary drug registration certificate for a vaccine against porcine circovirus type 2 [33] - Huanxu Electronics reported a 4% year-on-year increase in consolidated revenue for January 2026 [34] Group 12 - Xiangjia Co. reported a 10.42% year-on-year increase in live poultry sales revenue in January 2026 [35] - Kemin Foods' subsidiary reported a 68.29% year-on-year increase in pig sales revenue in January 2026 [36] - Liyuan Technology signed a procurement contract worth CNY 54.98 million [37] Group 13 - Jiuqiang Bio received a medical device registration certificate for a fibrin degradation product detection kit [38] - Zhongguancun's subsidiary passed the consistency evaluation for Tramadol Hydrochloride tablets [39] - Rundou Co. received a drug registration certificate for Candesartan Etil [40]

证券代码：600420 证券简称：国药现代 公告编号：2026-005 上海现代制药股份有限公司 关于全资子公司通过药品GMP符合性检查的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，上海现代制药股份有限公司（以下简称公司）全资子公司国药集团工 业有限公司（以下简称国药工业）下属的廊坊分公司收到药品 GMP 符合性检查 告知书，国药工业廊坊分公司的制剂 2 车间相关生产线通过 GMP 符合性检查。 现将相关情况公告如下： | 生产线名称 | 目前主要生产产品及设计产能 | | --- | --- | | 冻干粉针剂 生产线 2 | 注射用盐酸瑞芬太尼，设计产能 万支/年 750 | 一、基本信息 企业名称：国药集团工业有限公司廊坊分公司 生产地址：廊坊经济技术开发区创业路 检查范围：冻干粉针剂（制剂2车间 冻干粉针剂2生产线） 告知书编号：冀药监化药符（2026）19号 检查时间：2025年12月24日-2025年12月26日 检查结论：经现场检查和综合评定，符合《药品生产质量管理规范（2010 年修订）》及其附 ...

注射用盐酸瑞芬太尼用于全麻诱导和全麻维持过程中的镇静和镇痛。国内其他生产企业还有宜昌人福药 业有限责任公司和江苏恩华药业股份有限公司。 本次国药工业廊坊分公司的冻干粉针剂相关生产线通过药品GMP符合性检查，表明该新建生产线符合 《药品生产质量管理规范（2010年修订）》的要求，有利于公司稳定增加麻醉阵痛板块产品产能，以满 足相关药品的市场需求。上述事项对公司目前经营业绩不会产生重大影响。 格隆汇2月9日丨国药现代(600420.SH)公布，公司全资子公司国药集团工业有限公司（以下简称国药工 业）下属的廊坊分公司收到药品GMP符合性检查告知书，国药工业廊坊分公司的制剂2车间相关生产线 通过GMP符合性检查。 本次GMP符合性检查范围为国药工业廊坊分公司的冻干粉针剂（制剂2车间冻干粉针剂2生产线），系 冻干粉针剂增加"生产地址、生产线"的药品GMP符合性检查。该生产车间及生产线均为新建，建设总 投入约人民币9,282.77万元（未经审计）。 ...

证券日报网讯2月6日，国药现代（600420）在互动平台回答投资者提问时表示，未来公司将继续聚焦主 业发展，提升经营质量与盈利能力，并通过稳健经营和规范运作推动公司长期价值的持续释放。同时， 现金分红是上市公司回馈投资者、提升投资回报和市场认可度的重要方式，也是公司市值管理的重要组 成部分。 ...

Group 1 - The company, Guoyao Modern, produces various products including paracetamol tablets, acetaminophen and codeine tablets, lofecam and codeine tablets, and diclofenac sodium sustained-release tablets, which are used for antipyretic and analgesic purposes [2]

连续三年营收下滑，国药现代在2025年迎来了更坏的结局：营利双降。1月26日，国药现代发布业绩快 报，2025年实现营业总收入93.63亿元，同比下降14.4%；净利润9.44亿元，同比下降12.85%。过去三 年，在营收持续萎缩的背景下，国药现代净利润却逆势冲上历史高点，其秘密是削减了超过23亿元的销 售费用。然而，随着2025年营收与利润双双掉头向下，这种以费用换利润的财务策略，终究撞上了核心 业务"量价齐跌"的现实天花板。 业绩承压之下，国药现代于2025年7月挂牌转让子公司国药哈森51%股权，企图通过处理亏损资产"回 血"。不仅国药现代，"国药系"亦有多家上市公司呈现增长乏力态势，资产剥离与结构重整正不断上 演。 | 项目 | 本报告期 | 上年同期 | 增减变动幅度(%) | | --- | --- | --- | --- | | 营业总收入 | 9.363,062,749.56 | 10,937,525,114.43 | -14.40 | | 营业利润 | 1.314.013.493.87 | 1,751,923,513.42 | -25.00 | | 利润总额 | 1.328,198,785.7 ...